Methods for diagnosis and treatment of acute lymphoblastic leukemia
OwnerSmadar AVIGAD, Isaac YANIV +1inventors
InventorsSmadar AVIGAD, Isaac YANIV, Keren SHICHRUR
Life of this patent
Estimating the term…
Abstract
Provided herein is the use of miR-451 as a biomarker in prognosis of anti-ALL treatment modalities, in early diagnosis of ALL relapse risk, and/or in identifying an ALL patient that can benefit from a treatment modality that affects one or more miR-451-related metabolic pathways.
Claims16
A method for identifying acute lymphoblastic leukemia (ALL) patients most likely to benefit from treatment with a nicotinamide phosphoribosyl transferase (NAMPT) inhibitor, comprising:
- obtaining a biological sample from an ALL patient;
- determining a level of expression of miR-451 in the biological sample;
- and
- if the level of expression of miR-451 is below a predetermined level, identifying the patient as being likely to benefit from treatment with a NAMPT inhibitor.
A method for prognosis of a treatment modality that inhibits nicotinamide phosphoribosyl transferase (NAMPT) in a subject afflicted with acute lymphoblastic leukemia (ALL), the method comprising:
- obtaining a biological sample from the subject;
- determining a level of expression of miR-451 in the biological sample;
- and
- if the level of expression of miR-451 is below a predetermined level, correlating the level of expression of miR-451 with a positive prognosis of a treatment modality that inhibits NAMPT.
A method for treatment of acute lymphoblastic leukemia (ALL) in a patient suffering from ALL, comprising:
- obtaining a biological sample from the ALL patient;
- determining a level of expression of miR-451 in the biological sample;
- and
- if the level of expression of miR-451 is below a predetermined level, treating the patient with a nicotinamide phosphoribosyl transferase (NAMPT) inhibitor.
A method for early diagnosis of acute lymphoblastic leukemia (ALL) relapse risk in a subject, comprising:
- obtaining a biological sample from the subject when first diagnosed as inflicted with ALL;
- detecting a level of expression of miR-451;
- and
- diagnosing ALL relapse risk if the level of expression of miR-451 is below a predetermined level.
A method for treatment of pediatric acute lymphoblastic leukemia (ALL) in a subject, comprising:
- administering to the subject a therapeutically effective amount of an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), selected from the group consisting of an antibody, antisense nucleic acid, microRNA (miRNA) and RNA interference agent, thereby treating the patient, with the proviso that the inhibitor of NAMPT is not miR-451.
Dependencies are inferred from the claim text.